Switching from conventional antipsychotics to ziprasidone: A randomized, open-label comparison of regimen strategies

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 6, 2010, Pages 997-1000

  Stip, Emmanuel ^a,b   Zhornitsky, Simon ^a   Potvin, Stéphane ^a   Tourjman, Valerie ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Antipsychotic withdrawal; Atypical antipsychotic; Positive symptoms; Schizophrenia; Switch; Ziprasidone

Indexed keywords

FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; PIMOZIDE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARKINSONISM; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME;

EID: 77955056759     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.05.010     Document Type: Article

References (21)

1. Alptekin K., Hafez J., Brook S., et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol 2009, 24:229-238.
2. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676.
3. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 1991, 5:21-33.
4. Chouinard G., Chouinard V.A. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 2008, 77:69-77.
5. Chouinard G., Ross-Chouinard A., Annable L., et al. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980, 7:233.
6. Chue P., Stip E., Remington G., et al. Switching atypical antipsychotics: a review. Acta Neuropsychiatrica 2004, 16:301-313.
7. Ganguli R., Brar J.S., Mahmoud R., et al. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med 2008, 6:17.
8. Goudie A.J., Cole J.C. Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications. J Psychopharmacol 2008, 22:815-817.
9. Guy W. Early Clinical Drug Evaluation Manual, Washington, DC, United States Department of Health, Education, and Welfare 1976.
10. Llorca P.M., Vaiva G., Lancon C. Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal. Can J Psychiatry 2001, 46:87-88.
11. Margolese H.C., Chouinard G., Beauclair L., et al. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2002, 22:347-352.
12. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006, 114:3-13.
13. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Rep 1962, 10:799-812.
14. Pae C.U., Serretti A., Chiesa A., et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol 2009, 19:562-570.
15. Remington G., Chue P., Stip E., et al. The crossover approach to switching antipsychotics: what is the evidence?. Schizophr Res 2005, 76:267-272.
16. Seppala N., Kovio C., Leinonen E. Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. CNS Drugs 2005, 19:1049-1055.
17. Stip E., Anselmo K. Effectiveness of antipsychotics: is the CATIE trial a tsunami?. Can Fam Physician 2007, 53:97-98.
18. Tranter R., Healy D. Neuroleptic discontinuation syndromes. J Psychopharmacol 1998, 12:401-406.
19. Urbano M., Spiegel D., Rai A. Atypical antipsychotic withdrawal dyskinesia in 4 patients with mood disorders. J Clin Psychopharmacol 2007, 27:705-707.
20. Viguera A.C., Baldessarini R.J., Hegarty J.D., et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997, 54:49-55.
21. Weiden P.J., Aquila R., Dalheim L., et al. Switching antipsychotic medications. J Clin Psychiatry 1997, 58(Suppl 10):63-72.